Clinical Trials Browser

Phase 2/3 × Breast Neoplasms × Letrozole × Clear all

NCT03507465 2018-04-25

Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer

Phase 2/3 Unknown

Breast Neoplasms

NCT00684216 2017-09-14

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

Phase 2/3 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT00535418 2017-09-05

Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers

Phase 2/3 Completed

Breast Neoplasms

NCT00333047 2009-11-19

Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy

Phase 2/3 Completed

Breast Neoplasms